PrEP

Pre-Exposure Prophylaxis

Rocky Mountain CROI

 The 13th annual Conference on Retroviruses and Opportunistic Infections (CROI) took place in Denver, Colorado, from February 5 to 8. The major breaking news from this conference was the premature cancellation of the SMART study, but as usual, this important conference produced a great deal more than a single story.

PREParing the facts

Kirsty Machon questions the misinformation, controversy and conspiracy theories which put an end to the proposed PREP trials among sex workers in Cambodia and Cameroon.

Emerging information about the pathogenesis of HIV: implications for urgency of PEP and PREP Research

A summary of current research into CD4 cell loss in early infection and its implications for HIV prevention, by NAPWA policy analyst Kirsty Machon.

Cambodian PREP trial halted

A controversial Cambodian trial of tenofovir for pre-exposure prophylaxis (PREP) is unlikely to proceed after sex workers and the Cambodian government claimed the trial did not include adequate safeguards for the health and human rights of the participants.

Pre-exposure prophylaxis study for Cambodia

Australian researchers have teamed up with the US and Cambodia to conduct a study of the potential of the HIV antiviral tenofovir, taken daily, to prevent HIV infection in women at high risk.

Female sex workers, who in Cambodia currently stand up to a 26 percent chance of becoming HIV-infected within their first year working in the sex industry, will be invited to participate in a ground-breaking study which researchers acknowledge is challenging, but necessary.